Glioblastomas (GBM) are among the most aggressive and therapy-resistant tumors of the central nervous system and present both clinicians and researchers with immense challenges. Despite significant advances in diagnostics and an improvement in standard therapy, which usually consists of surgical resection, subsequent radiotherapy and the administration of temozolomide, the survival prospects are still unsatisfactory. This is mainly due to the pronounced resistance, the complex tumor heterogeneity and the immunomodulating properties of glioblastoma cells and their microenvironment.
You May Also Like
- Practice Management
Improved quality of care aims for satisfied patients
- Chemsex - MSM, sex, chrystal meth & co.
Medical and psychosocial perspectives
- Bladder cancer
Tuberculosis vaccination reduces recurrences
- Oral JAK-i in atopic dermatitis
Benefits and risks: What does the current data say?
- Sleep-wake disorders in pneumology practice
Patience, knowledge and persistence in therapy
- Chronic lung diseases
Sarcopenia and malnutrition in the context of pneumological rehabilitation
- Cardiovascular risk and obesity
Pathomechanisms, secondary prevention and treatment options
- Oxidative stress and neurodegeneration